학술논문

Erratum to ‘Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors’: [ESMO Open Volume 7, Issue 2, April 2022, 100447]
Document Type
Erratum
Source
In ESMO Open August 2022 7(4)
Subject
Language
ISSN
2059-7029